Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 5/2008

01-10-2008 | Case Report

A case with life-threatening interstitial pneumonia associated with bucillamine treatment

Authors: Yuiko Ogiwara, Hideaki Mochizuki, Takehiko Morioka, Takahiko Sugihara, Fumihiko Makino, Hideki Takahashi

Published in: Modern Rheumatology | Issue 5/2008

Login to get access

Abstract

We report a case of bucillamine-induced interstitial pneumonia accompanied by severe hypoxemia in an 83-year-old woman who had rheumatoid arthritis. Respiratory failure worsened even after withdrawal of bucillamine and administration of high-dose corticosteroids, and mechanical ventilation was required. A review of 15 cases with bucillamine-induced pulmonary injury suggests that advanced age may be associated with the development of severe interstitial pneumonia. Bucillamine can cause corticosteroid-resistant and life-threatening lung injury, especially in the elderly.
Literature
1.
Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with rheumatoid arthritis. Mod Rheumatol. 2006;16:85–91.
2.
Hara A, Sakamoto O, Matsumoto M, et al. A case of bucillamine-induced interstitial pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30:1743–8 (in Japanese).PubMed
3.
Tanaka H, Nakahara K, Goto K. A case of bucillamine-induced pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi. 1992;30:695–701 (in Japanese).PubMed
4.
Inokuma S, Sakata M, Yoshida A, Shiratori K, Kiyosawa H. Bucillamine induced pulmonary injury occurs with immunoglobulin decrease. J Rheumatol. 1996;23:1282–5.PubMed
5.
Fukino K, Shiota T, Nakaya Y, et al. A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamone. Bronchology. 1997;19:232–6 (in Japanese).
6.
Lee YH, Kim YR, Ji JD, et al. A case of BOOP developed during bucillamine treatment for rheumatoid. Korean J Intern Med. 2001;16:36–9.PubMed
7.
Matsushima H, Takayanagi N, Sakamoto T, et al. A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamine. Nihon Kokyuki Gakkai Zasshi. 2001;39(1):55–9 (in Japanese).PubMed
8.
Miwa Y, Kaga S, Hanaoka R, et al. A case of rheumatoid arthritis complicated with a pneumonitis during concomitant treatment with methotrexate and bucillamine. Ryumachi. 2002;42:70–5 (in Japanese).PubMed
9.
Kishimoto N, Fujii K. A case of pulmonary infiltration with eosinophilia (PIE) syndrome induced by bucillamine treatment of rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2002;40:321–5 (in Japanese).PubMed
10.
Tanimura K, Shimizu M, Matsuhashi M, Shinohara M, Sagawa A. A case of interstitial pneumonia caused by bucillamine: a study using serological markers. Mod Rheumatol. 2006;16:39–43.PubMedCrossRef
11.
Nanke Y, Yamada T, Kamatani N. Asymptomatic interstitial pneumonitis induced by bucillamine in a patient with rheumatoid arthritis. Mod Rheumatol. 2005;15:381–2.PubMedCrossRef
12.
Kajiya T, Kuroda A, Hokonohara D, Tei C. Radiographic appearance of bronchiolitis obliterans organizing pneumonia (BOOP) developing during Bucillamine treatment for rheumatoid arthritis. Am J Med Sci. 2006;332:39–42.PubMedCrossRef
13.
Saito Y, Nei T, Abe S, et al. A case of bucillamine-induced interstitial pneumonia with positive lymphocyte stimulation test for bucillamine using bronchoalveolar lavage lymphocytes. Intern Med. 2007;46:1739–43.PubMedCrossRef
14.
Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.PubMedCrossRef
15.
16.
Negishi M, Kaga S, Kasama T, et al. Lung injury associated with bucillamine therapy. Ryumachi. 1992;32:135–9 (in Japanese).PubMed
17.
Kurashima K, Nakao S, Fujimura M, Matsuda T. Bucillamine-induced hypersensitivity pneumonitis. Chest. 1992;101:1479–80.PubMedCrossRef
18.
Battaglia S, Sandrini MC, Catalano F, et al. Effects of aging on sensation of dyspnea and health-related quality of life in elderly asthmatics. Aging Clin Exp Res. 2005;17:287–92.PubMed
Metadata
Title
A case with life-threatening interstitial pneumonia associated with bucillamine treatment
Authors
Yuiko Ogiwara
Hideaki Mochizuki
Takehiko Morioka
Takahiko Sugihara
Fumihiko Makino
Hideki Takahashi
Publication date
01-10-2008
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 5/2008
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-008-0083-7

Other articles of this Issue 5/2008

Modern Rheumatology 5/2008 Go to the issue

Original Article

Tristetraprolin (TTP) gene polymorphisms in patients with rheumatoid arthritis and healthy individuals

Original Article

Comparison between resection arthroplasty alone and resection arthroplasty with arthrodesis of the first MTP joint for rheumatoid forefoot deformities

Case Report

Total knee arthroplasty for rheumatoid knee with bilateral, severe flexion contracture: report of three cases

Original Article

Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjögren’s syndrome

Letter

Pulmonary hemorrhage, due to rupture of small muscular arteries, in an autopsy case of systemic lupus erythematosus with antiphospholipid antibodies

Case Report

Enthesitis-related arthritis in Kikuchi–Fujimoto disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits